Ibrahim Al-Sanouri, MD
Pulmonary Disease · Madison, WINPI 1356452833
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 46.5% of the total. 2025 is the largest year on record at $4,174, 2.6 times the $1,581 reported in 2019.
Across 144 payments — averaging $51.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Veran Medical Technologies, Inc.$1K
- GSK$486
- Amgen$415
- Regeneron Healthcare Solutions, Inc.$340
- AstraZeneca$250
- plus $1K from 29 others
What the payments were for
- Travel & lodging$1,94126%
- Food & beverage$2,79637%
- Education$2,73337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,471 |
| Veran Medical Technologies, Inc. | 3 | $1,316 |
| GSK | 28 | $486 |
| Amgen | 24 | $415 |
| Regeneron Healthcare Solutions, Inc. | 10 | $340 |
| AstraZeneca(2 entities) | 16 | $250 |
| Sanofi | 9 | $197 |
| Boehringer Ingelheim | 6 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 4 | $92 |
| Inspire Medical Systems, Inc. | 1 | $76 |
| Mylan Specialty L.p. | 4 | $74 |
| Baxter Healthcare | 2 | $48 |
| Harmony Biosciences LLC | 2 | $46 |
| Pulmonx Corporation | 2 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Circassia Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Electromed, Inc. | 2 | $25 |
| Pfizer | 1 | $24 |
| Resmed Corp | 1 | $22 |
| Novartis | 1 | $22 |
| United Therapeutics Corporation | 1 | $20 |
| 3b Medical, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Bard Access Systems, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,424
- Spin$1,316
How this compares
$7,470 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 260 | $970,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 307 | $289,293 |
| Fasenra PenBenralizumab | 37 | $207,152 |
| TezspireTezepelumab-Ekko | 46 | $199,686 |
| NucalaMepolizumab | 15 | $54,676 |
| Spiriva RespimatTiotropium Bromide | 53 | $45,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $41,162 |
| XolairOmalizumab | 16 | $30,658 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $21,934 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $20,707 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $19,226 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,311 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $8,708 |
| Ventolin HfaAlbuterol Sulfate | 85 | $8,235 |
| Atrovent HfaIpratropium Bromide | 14 | $7,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $486 | $379,753378 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $250 | $262,782151 claims |
| Boehringer IngelheimSpiriva Respimat | $109 | $45,82753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Madison
- Nizar JarjourMadison$35K
- Andrew BraunMadison$33K
- John FergusonMadison$32K
- Stephen HallidayMadison$12K
- Taeha KimMadison$10K
- Mounir FertikhMadison$8K
- Arwa Al-BedourMadison$7K
- Amy JaegerMadison$5K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.